JMP Securities reissued their mkt outperform rating on shares of Syros Pharmaceuticals (NASDAQ:SYRS) in a research report released on Friday morning, Marketbeat reports. The brokerage currently has a $18.00 price objective on the stock.
Several other brokerages also recently issued reports on SYRS. BidaskClub raised shares of Syros Pharmaceuticals from a sell rating to a hold rating in a research note on Tuesday, December 11th. Roth Capital set a $12.00 price objective on shares of Syros Pharmaceuticals and gave the company a buy rating in a research note on Thursday, November 15th. Oppenheimer set a $26.00 price objective on shares of Syros Pharmaceuticals and gave the company a buy rating in a research note on Tuesday, November 13th. HC Wainwright reissued a hold rating and set a $10.00 price objective on shares of Syros Pharmaceuticals in a research note on Friday. Finally, Wedbush reissued an outperform rating and set a $13.00 price objective on shares of Syros Pharmaceuticals in a research note on Monday, December 3rd. One research analyst has rated the stock with a sell rating, three have given a hold rating and five have issued a buy rating to the company. The company currently has a consensus rating of Hold and an average target price of $15.29.
Shares of SYRS opened at $6.58 on Friday. The company has a market cap of $216.74 million, a P/E ratio of -3.09 and a beta of 1.14. Syros Pharmaceuticals has a 1 year low of $5.17 and a 1 year high of $13.86.
In other Syros Pharmaceuticals news, major shareholder Venture Fund Vii L.P. Arch sold 164,583 shares of the stock in a transaction that occurred on Monday, March 11th. The shares were sold at an average price of $6.80, for a total transaction of $1,119,164.40. The transaction was disclosed in a filing with the SEC, which is available at this link. Company insiders own 27.80% of the company’s stock.
A number of large investors have recently bought and sold shares of SYRS. Northern Trust Corp raised its stake in Syros Pharmaceuticals by 52.2% during the second quarter. Northern Trust Corp now owns 275,638 shares of the company’s stock worth $2,814,000 after purchasing an additional 94,548 shares during the period. Wedge Capital Management L L P NC purchased a new position in Syros Pharmaceuticals during the third quarter worth approximately $731,000. JPMorgan Chase & Co. raised its stake in Syros Pharmaceuticals by 2.3% during the third quarter. JPMorgan Chase & Co. now owns 369,959 shares of the company’s stock worth $4,406,000 after purchasing an additional 8,286 shares during the period. ARK Investment Management LLC raised its stake in Syros Pharmaceuticals by 23.5% during the third quarter. ARK Investment Management LLC now owns 2,221,870 shares of the company’s stock worth $26,462,000 after purchasing an additional 422,317 shares during the period. Finally, Bank of New York Mellon Corp raised its stake in Syros Pharmaceuticals by 10.0% during the third quarter. Bank of New York Mellon Corp now owns 77,654 shares of the company’s stock worth $925,000 after purchasing an additional 7,062 shares during the period. 63.47% of the stock is currently owned by institutional investors.
About Syros Pharmaceuticals
Syros Pharmaceuticals, Inc, a biopharmaceutical company, focuses on the development of treatment for cancer and monogenic diseases, and building a pipeline of gene control medicines. Its lead product candidates include SY-1425, a selective retinoic acid receptor alpha agonist, which is in a Phase II clinical trial for genomically defined subsets of patients with acute myeloid leukemia (AML) and myelodysplastic syndrome; and SY-1365, a selective CDK7 inhibitor, which is in a Phase I clinical trial that is used for treating patients with solid tumors and blood cancers, including ovarian cancer, breast cancer, and AML.
Recommended Story: What is a Derivative?
Receive News & Ratings for Syros Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Syros Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.